Molecular Cancer

As an internationally recognized journal, Molecular Cancer is dedicated to the innovation of how basic cancer research drives advances in cancer prevention, ...

List of Papers (Total 5,055)

Reprogramming cellular senescence and aging clocks for advanced cancer immunotherapy

Cellular senescence has gradually been recognized as a key process, which not only inhibits the occurrence of early tumors but also promotes advanced malignant progression through secretory and immunomodulatory functions. Initially, cellular senescence manifested as irreversible cell cycle arrest, but now it encompasses a broader phenotype regulated by the p53-p21CIP1 and...

Hsa_circ_0038737 promotes PARPi resistance in castration-resistant prostate cancer via IGF2BP3-mediated DNPH1 mRNA stabilization

Resistance to poly (ADP-ribose) polymerase inhibitors (PARPi) poses a major challenge to therapeutic efficacy in castration-resistant prostate cancer (CRPC). Although circular RNAs (circRNAs) have emerged as critical regulators in cancer biology, their involvement in PARPi resistance remains largely uncharacterized. This study aims to elucidate the molecular mechanism by which...

BRD9-p53-E2F1 circuit orchestrates cell growth and DNA damage repair in gastric cancer

BRD9 is involved in multiple physiological and pathological pathways, yet its functional role and molecular mechanisms in gastric cancer (GC) remain largely unexplored. Addressing this knowledge gap is critical given the persistent global mortality burden of GC and the limited efficacy of current therapeutic strategies. BRD9 expression in GC patients was systematically analyzed...

Microbiome-metabolome interplay in pancreatic cancer progression: insights from multi-omics analysis

Recent studies suggest that intratumoral microbiome and altered metabolic networks play crucial roles in pancreatic cancer (PC) progression. However, the precise interplay between microbial communities and tumor metabolism in PC remains poorly understood. This study aims to investigate the impact of the intratumoral microbiome, the metabolic landscape, and their interactions on...

HPGD induces ferroptosis and autophagy to suppress esophageal squamous cell carcinoma through the LXA4–ERK1/2–U2AF2–TFRC axis

Although 15-hydroxyprostaglandin dehydrogenase (HPGD) is known to regulate the metabolism of prostaglandins and lipoxin A4, and its dysregulation has been implicated in various cancers, its role in esophageal squamous cell carcinoma (ESCC) has not been determined. This study is the first to comprehensively characterize HPGD expression in ESCC and establish its clinical relevance...

The role of acetylcholine and its receptors in tumor immune regulation: mechanisms and potential therapeutic targets

Acetylcholine (ACh) is an essential neurotransmitter that has recently gained attention for its multifunctional role in tumor immune regulation. By binding neuronal loss to nicotinic and muscarinic receptors, ACh directly promotes tumor cell proliferation and migration while modulating immune cell functions, thereby influencing the tumor microenvironment. Additionally, ACh plays...

Epigenetic modification of cuproptosis by non-coding RNAs in cancer drug resistance

Tumor drug resistance remains a significant barrier to effective cancer treatment, undermining the clinical efficacy of current therapies through adaptive and evolving mechanisms. Cuproptosis, a recently discovered form of programmed cell death, emerges as a promising tumor suppressor by targeting mitochondrial metabolic pathways, offering a novel strategy to combat drug...

Multifunctional gold nanoparticles: bridging detection, diagnosis, and targeted therapy in cancer

Cancer remains a leading global health challenge, responsible for millions of deaths annually. Conventional therapies are hindered by systemic toxicity, drug resistance, and ineffective targeting of the tumor microenvironment (TME). Gold nanoparticles (AuNPs) have emerged as promising tools in oncology, offering unique plasmonic properties, high biocompatibility, and the ability...

Evolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs

The RAS signaling pathway, particularly through mutations in KRAS, NRAS, and HRAS, plays a pivotal role in driving oncogenesis in a wide range of cancers. For years, RAS proteins were deemed "undruggable

Retraction Note: Long non-coding RNA PVT1 promotes tumor progression by regulating the miR-143/HK2 axis in gallbladder cancer

This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s12943-019-0947-9.

Engineered iron oxide nanoplatforms: reprogramming immunosuppressive niches for precision cancer theranostics

Iron oxide nanoparticles (IONPs) have transitioned from conventional magnetic resonance imaging (MRI) contrast agents into structurally programmable combined imaging/treatment tools, leveraging their superparamagnetism, catalytic activity, and surface engineering versatility to achieve spatiotemporal control over drug delivery and immune modulation. Advances in nanofabrication...

Advances in novel cell death mechanisms in breast cancer: intersecting perspectives on ferroptosis, cuproptosis, disulfidptosis, and pyroptosis

The advent of molecular classification has ushered breast cancer treatment into the era of precision medicine. Nevertheless, clinical management continues to face significant challenges posed by drug resistance and tumor heterogeneity. Recent advances have identified novel programmed cell death (PCD) mechanisms-including ferroptosis, cuproptosis, disulfidptosis, and pyroptosis-as...

Retraction Note: m6A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling

This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s12943-019-1128-6.

Single-cell multi-omics in cancer immunotherapy: from tumor heterogeneity to personalized precision treatment

Cancer immunotherapy has revolutionized clinical oncology; however, the inherent complexity and heterogeneity of cancer present substantial challenges to achieving broad therapeutic efficacy. Tumor heterogeneity manifests not only among different patients but also within individual tumors, further complicating personalized treatment approaches. Single-cell sequencing technologies...

The application of organoids in treatment decision-making for digestive system cancers: progress and challenges

Digestive system cancers—including gastric, liver, colorectal, esophageal, and pancreatic malignancies—remain leading causes of cancer death, with treatment resistance posing major challenges in advanced disease. Patient-derived cancer organoids (PDCOs), 3D mini-tumors grown from patient biopsies, have revolutionized personalized oncology by faithfully replicating tumor biology...

Biomolecular phase separation in tumorigenesis: from aberrant condensates to therapeutic vulnerabilities

Biomolecular phase separation has emerged as a fundamental mechanism governing intracellular spatial organization and functional compartmentalization, and is increasingly recognized as a critical factor in tumor initiation and progression. Through multivalent molecular interactions, biomolecular phase separation contributes to the formation of condensates that mediate the...

Oxidative stress in cancer: from tumor and microenvironment remodeling to therapeutic frontiers

Oxidative stress is a pathological condition of redox signaling dysregulation and macromolecular oxidative damage arising from elevated ROS levels. Oxidative stress interacts with tumor cell growth regulation and tumor microenvironment remodeling, and has been a critical hallmark of cancer. Targeting oxidative stress has garnered great attention in cancer therapy development...

CircZFR/YTHDF3 axis drives lymph node metastasis in cervical cancer via FASN translation

Lymph node metastasis is a key driver of poor outcomes in cervical cancer. However, the molecular mechanisms of circular RNAs (circRNAs) driving cervical cancer lymph node metastasis remain unclear. We identified circZFR, fatty acid synthase (FASN) and YTH N6-methyladenosine RNA binding protein F3 (YTHDF3) protein expression in the cervical cancer patients with long and short...

Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancer

Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype associated with the highest mortality rate among all breast cancer subtypes, primarily due to the absence of actionable therapeutic targets. Although poly (ADP-ribose) polymerase inhibitors (PARPi) have shown promising therapeutic effects in TNBC patients harboring homologous recombination...

Neurotransmitters: an emerging target for therapeutic resistance to tumor immune checkpoint inhibitors

The critical role of neurotransmitters in the resistance to tumor immune checkpoint inhibitor (ICI) is becoming increasingly significant in therapeutic contexts. ICIs work by enhancing antitumor immunity through the blockade of the PD-1/PD-L1 and CTLA-4 pathways. However, only 20% of patients experience durable efficacy, and the challenge of drug resistance limits the clinical...

Integrating neuroscience and oncology: neuroimmune crosstalk in the initiation and progression of digestive system tumors

Recent global data show that cancers of the digestive system are responsible for approximately one-third of all cancer-related deaths worldwide, underscoring the urgent need for innovative therapeutic strategies. In this context, emerging findings from neuroscience may unveil new avenues for tackling this pressing clinical problem. Over the past few years, rapid progress in...

Cellular senescence in cancer: from mechanism paradoxes to precision therapeutics

Cellular senescence is a double-edged sword in cancer biology, functioning as both a tumor-suppressive mechanism and a driver of malignancy. Initially, senescence acts as a protective barrier by arresting the proliferation of damaged or oncogene-expressing cells via pathways such as oncogene-induced senescence and the DNA damage response. However, persistent senescence-associated...

Unraveling the glyco-immunity nexus in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive disease, and standard of care therapies have failed to yield significant clinical benefit, with invasive surgery being the only curative treatment for patients with early-stage disease. Tumor-associated glycans in pancreatic cancer have direct effects on the survival and propagation of the tumor proper and...